Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Debt to Equity (2016 - 2025)

Cytosorbents (CTSO) has disclosed Debt to Equity for 9 consecutive years, with $1.61 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Debt to Equity rose 56.55% year-over-year to $1.61, compared with a TTM value of $1.61 through Sep 2025, up 56.55%, and an annual FY2024 reading of $1.26, up 486.72% over the prior year.
  • Debt to Equity was $1.61 for Q3 2025 at Cytosorbents, up from $1.24 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.61 in Q3 2025 and bottomed at $0.14 in Q4 2022.
  • Average Debt to Equity over 4 years is $0.72, with a median of $0.78 recorded in 2024.
  • The sharpest move saw Debt to Equity soared 51.95% in 2023, then surged 486.72% in 2024.
  • Year by year, Debt to Equity stood at $0.14 in 2022, then soared by 51.95% to $0.21 in 2023, then soared by 486.72% to $1.26 in 2024, then rose by 28.16% to $1.61 in 2025.
  • Business Quant data shows Debt to Equity for CTSO at $1.61 in Q3 2025, $1.24 in Q2 2025, and $0.98 in Q1 2025.